NCT03584750

Brief Summary

In recent years there has been a novel approach for the treatment of chronic pain: Floatation REST (restricted environmental stimulation therapy). Floating is a therapeutic approach, in which patients float in a specialized pool or tank on water that contains high concentrations of Epsom salt (Magnesium sulfate). Water is kept at skin temperature (35-36°C) and the pool or tank is shielded to provide almost complete darkness and silence. This therapeutic approach has proven to be effective in alleviating chronic pain. Due to the difficulties associated with designing a credible placebo control there have been no randomized controlled trials (RCTs) with patients blinding so far. Such blinding, however, is crucial, to assess the true therapeutic effect of the intervention. The investigators will conduct the first patient blinded RCT of Floatation REST for chronic pain with a credible placebo control for floating and a no-treatment group.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
99

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 11, 2018

Completed
15 days until next milestone

Study Start

First participant enrolled

June 26, 2018

Completed
16 days until next milestone

First Posted

Study publicly available on registry

July 12, 2018

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 2, 2020

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 18, 2020

Completed
Last Updated

November 24, 2020

Status Verified

November 1, 2020

Enrollment Period

1.5 years

First QC Date

June 11, 2018

Last Update Submit

November 23, 2020

Conditions

Keywords

Somatic and psychological factors

Outcome Measures

Primary Outcomes (1)

  • Change in Pain intensity (maximum and average) as compared to baseline

    Numeric rating scales from 0 ("no pain") to 100 ("maximum imaginable pain"), assessing retrospectively the week before.

    1, 12 and 24 weeks after intervention

Secondary Outcomes (22)

  • Change in Pain scores (maximum and average, dichotomous) as compared to baseline

    1, 12 and 24 weeks after intervention

  • Change in pain-related disability as compared to baseline

    1, 12 and 24 weeks after intervention

  • Change in trait anxiety as compared to baseline

    1, 12 and 24 weeks after intervention

  • Change in depression as compared to baseline

    1, 12 and 24 weeks after intervention

  • Change in physical and mental health as compared to baseline

    1, 12 and 24 weeks after intervention

  • +17 more secondary outcomes

Study Arms (3)

Intervention group

ACTIVE COMPARATOR

Floating

Other: Floating

Control group

PLACEBO COMPARATOR

Placebo floating

Other: Placebo floating

No-treatment group

NO INTERVENTION

Waiting list

Interventions

Floating in specialized tank with full floatation and sensory deprivation.

Also known as: Floatation REST
Intervention group

Floating in specialized tank with reduced floatation and sensory deprivation.

Control group

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Current diagnosis of chronic pain disorder with somatic and psychological factors (German ICD F45.41)
  • Able and willing to give written informed consent

You may not qualify if:

  • Pregnant or nursing women (self report)
  • Previous experience with floating
  • Acute illnesses that may exacerbate or shadow the chronic pain condition (acute inflammation, major depression, active neoplasm, etc.)
  • History of alcohol and drug abuse
  • Any clinically relevant abnormal findings in the clinical history, which, in the opinion of the investigator, may either put the subject at risk because of participation in the study or may influence the results of the study or the subject's ability to participate in the study.
  • Any clinical condition that may prevent the subject from floating, such as: open injuries, contagious diseases (influenza, GI infections, athlete's foot), GERD, epilepsy, claustrophobia, schizophrenia, incontinence or acute skin disorders.
  • Suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hannover Medical School

Hanover, 30625, Germany

Location

Related Publications (1)

  • Loose LF, Manuel J, Karst M, Schmidt LK, Beissner F. Flotation Restricted Environmental Stimulation Therapy for Chronic Pain: A Randomized Clinical Trial. JAMA Netw Open. 2021 May 3;4(5):e219627. doi: 10.1001/jamanetworkopen.2021.9627.

MeSH Terms

Interventions

Divorce

Intervention Hierarchy (Ancestors)

Marital StatusFamily CharacteristicsDemographyPopulation CharacteristicsSocioeconomic Factors

Study Officials

  • Florian Beissner, Dr. phil. nat.

    Hannover Medical School

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 11, 2018

First Posted

July 12, 2018

Study Start

June 26, 2018

Primary Completion

January 2, 2020

Study Completion

June 18, 2020

Last Updated

November 24, 2020

Record last verified: 2020-11

Locations